- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01396668
Fixed Dose Rate Gemcitabine and Cisplatin Followed by Chemoradiation for Locally Advanced Pancreatic Cancer
July 15, 2011 updated by: Seoul National University Hospital
Phase Ⅱ Trial of Fixed Dose Rate Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiation With Capecitabine in Patients With Locally Advanced Pancreatic Cancer
This is a phase Ⅱ trial of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The main purpose of this study is to evaluate the efficacy and safety of fixed dose rate gemcitabine and cisplatin chemotherapy followed by chemoradiation with capecitabine in patients with locally advanced pancreatic cancer.
Study Type
Interventional
Enrollment (Anticipated)
35
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seongnam, Korea, Republic of
- Seoul National University Bundang Hospital
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- unresectable locally advanced pancreatic cancer
- no distant metastasis
- histologically confirmed adenocarcinoma of pancreas
- 18-75 of age
- ECOG performance status 0-2
normal marrow function :
- WBC at least 3,000/mm3 OR Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
normal liver function :
--Bilirubin no greater than 2.0 mg/dL AST less than 3 times upper limit of normal (ULN)
normal renal function :
--Creatinine no greater than 1.5 times ULN
- signed informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Time to progression
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival
Time Frame: 1 year
|
1 year
|
|
|
safety
Time Frame: 12 months
|
number of patients who experienced grade 3-4 toxicity by NCI-CTCAE
|
12 months
|
|
1 year survival rate
Time Frame: 1 year
|
1 year
|
|
|
response rate
Time Frame: 1 year
|
response rate by RECIST criteria
|
1 year
|
|
clinical benefit rate
Time Frame: 1 year
|
CR+PR+SD by RECIST criteria
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Seock-Ah Im, MD, PhD, Seoul National University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2004
Primary Completion (Actual)
June 1, 2011
Study Completion (Actual)
June 1, 2011
Study Registration Dates
First Submitted
July 1, 2011
First Submitted That Met QC Criteria
July 15, 2011
First Posted (Estimate)
July 19, 2011
Study Record Updates
Last Update Posted (Estimate)
July 19, 2011
Last Update Submitted That Met QC Criteria
July 15, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
- Capecitabine
Other Study ID Numbers
- H-0412-138-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.